References
1. Nicosia S, Capra V, Rovati GE. Leukotrienes as mediators of asthma.Pulmonary Pharmacology & Therapeutics. 2001;14(1):3-19.
2. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE.
Cysteinyl-leukotrienes and their receptors in asthma and other
inflammatory diseases: Critical update and emerging trends. Med
Res Rev. 2007;27(4):469-527.
3. Folco G, Rossoni G, Buccellati C, Berti F, Maclouf J, Sala A.
Leukotrienes in cardiovascular diseases. Am J Respir Crit Care
Med. 2000;161(2 Pt 2):S112-116.
4. Back M. Leukotriene signaling in atherosclerosis and ischemia.Cardiovasc Drugs Ther. 2009;23(1):41-48.
5. Poeckel D, Funk CD. The 5-Lipoxygenase/Leukotriene Pathway in
Preclinical Models of Cardiovascular Disease. Cardiovasc Res.2010.
6. Capra V, Back M, Barbieri SS, Camera M, Tremoli E, Rovati GE.
Eicosanoids and their drugs in cardiovascular diseases: focus on
atherosclerosis and stroke. Med Res Rev. 2013;33(2):364-438.
7. Brezinski DA, Nesto RW, Serhan CN. Angioplasty triggers intracoronary
leukotrienes and lipoxin A4. Impact of aspirin therapy.Circulation. 1992;86(1):56-63.
8. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW,
Tagari P. Increased urinary leukotriene excretion in patients with
cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.Circulation. 1992;85(1):230-236.
9. Allen SP, Sampson AP, Piper PJ, Chester AH, Ohri SK, Yacoub MH.
Enhanced excretion of urinary leukotriene E4 in coronary artery disease
and after coronary artery bypass surgery. Coron Artery Dis.1993;4(10):899-904.
10. De Caterina R, Giannessi D, Lazzerini G, et al. Sulfido-peptide
leukotrienes in coronary heart disease - relationship with disease
instability and myocardial ischaemia. Eur J Clin Invest.2010;40(3):258-272.
11. Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene
constrictor responses in human atherosclerotic coronary arteries.Circulation. 1998;97(24):2406-2413.
12. Lotzer K, Spanbroek R, Hildner M, et al. Differential leukotriene
receptor expression and calcium responses in endothelial cells and
macrophages indicate 5-lipoxygenase-dependent circuits of inflammation
and atherogenesis. Arterioscler Thromb Vasc Biol.2003;23(8):e32-36.
13. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the
5-lipoxygenase pathway within the arterial wall during human
atherogenesis. Proc Natl Acad Sci U S A. 2003;100(3):1238-1243.
14. Di Gennaro A, Wagsater D, Mayranpaa MI, et al. Increased expression
of leukotriene C4 synthase and predominant formation of
cysteinyl-leukotrienes in human abdominal aortic aneurysm. Proc
Natl Acad Sci U S A. 2010;107(49):21093-21097.
15. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding
5-lipoxygenase activating protein confers risk of myocardial infarction
and stroke. Nat Genet. 2004;36(3):233-239.
16. Iovannisci DM, Lammer EJ, Steiner L, et al. Association between a
leukotriene C4 synthase gene promoter polymorphism and coronary artery
calcium in young women: the Muscatine Study. Arterioscler Thromb
Vasc Biol. 2007;27(2):394-399.
17. Bevan S, Lorenz MW, Sitzer M, Markus HS. Genetic variation in the
leukotriene pathway and carotid intima-media thickness: a 2-stage
replication study. Stroke. 2009;40(3):696-701.
18. Freiberg JJ, Tybjaerg-Hansen A, Nordestgaard BG. Novel mutations in
leukotriene C(4) synthase and risk of cardiovascular disease based on
genotypes from 50,000 individuals. J Thromb Haemost.2010;8(8):1694-1701.
19. Capra V, Ambrosio M, Riccioni G, Rovati GE. Cysteinyl-leukotriene
receptor antagonists: present situation and future opportunities.Curr Med Chem. 2006;13(26):3213-3226.
20. Ross R. Atherosclerosis–an inflammatory disease. N Engl J
Med. 1999;340(2):115-126.
21. Back M, Hansson GK. Anti-inflammatory therapies for atherosclerosis.Nat Rev Cardiol. 2015;12(4):199-211.
22. Sala A, Rossoni G, Berti F, et al. Monoclonal anti-CD18 antibody
prevents transcellular biosynthesis of cysteinyl leukotrienes in vitro
and in vivo and protects against leukotriene-dependent increase in
coronary vascular resistance and myocardial stiffness.Circulation. 2000;101(12):1436-1440.
23. Bäck M. Leukotriene receptors: crucial components in vascular
inflammation. ScientificWorldJournal. 2007;7:1422-1439.
24. Back M, Powell WS, Dahlen SE, et al. International Union of Basic
and Clinical Pharmacology. Update on Leukotriene, Lipoxin and
Oxoeicosanoid Receptors: IUPHAR Review 7. Br J Pharmacol.2014;171(15):3551-3574.
25. Funk CD. Leukotriene modifiers as potential therapeutics for
cardiovascular disease. Nat Rev Drug Discov. 2005;4(8):664-672.
26. Back M, Dahlen SE, Drazen JM, et al. International Union of Basic
and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature,
distribution, and pathophysiological functions. Pharmacol Rev.2011;63(3):539-584.
27. Di X, Tang X, Di X. Montelukast inhibits oxidized low-density
lipoproteins (ox-LDL) induced vascular endothelial attachment: An
implication for the treatment of atherosclerosis. Biochem Biophys
Res Commun. 2017;486(1):58-62.
28. Di Gennaro A, Araujo AC, Busch A, et al. Cysteinyl leukotriene
receptor 1 antagonism prevents experimental abdominal aortic aneurysm.Proc Natl Acad Sci U S A. 2018;115(8):1907-1912.
29. Hoxha M, Rovati GE, Cavanillas AB. The leukotriene receptor
antagonist montelukast and its possible role in the cardiovascular
field. Eur J Clin Pharmacol. 2017;73:799-809.
30. Allayee H, Hartiala J, Lee W, et al. The effect of montelukast and
low-dose theophylline on cardiovascular disease risk factors in
asthmatics. Chest. 2007;132(3):868-874.
31. Ingelsson E, Yin L, Back M. Nationwide cohort study of the
leukotriene receptor antagonist montelukast and incident or recurrent
cardiovascular disease. J Allergy Clin Immunol.2012;129(3):702-707.
32. Tajeu GS, Booth JN, 3rd, Colantonio LD, et al. Incident
Cardiovascular Disease Among Adults With Blood Pressure
<140/90 mm Hg. Circulation. 2017;136(9):798-812.
33. Austin PC. Optimal caliper widths for propensity-score matching when
estimating differences in means and differences in proportions in
observational studies. Pharm Stat. 2011;10(2):150-161.
34. Rovati GE, Sala A, Capra V, Dahlen SE, Folco G. Dual COXIB/TP
antagonists: a possible new twist in NSAID pharmacology and
cardiovascular risk. Trends Pharmacol Sci. 2010;31(3):102-107.
35. Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a
5-lipoxygenase-activating protein inhibitor on biomarkers associated
with risk of myocardial infarction: a randomized trial. Jama.2005;293(18):2245-2256.
36. Iribarren C, Tolstykh IV, Miller MK, Sobel E, Eisner MD. Adult
asthma and risk of coronary heart disease, cerebrovascular disease, and
heart failure: a prospective study of 2 matched cohorts. Am J
Epidemiol. 2012;176(11):1014-1024.
37. Tattersall MC, Guo M, Korcarz CE, et al. Asthma predicts
cardiovascular disease events: the multi-ethnic study of
atherosclerosis. Arterioscler Thromb Vasc Biol.2015;35(6):1520-1525.
38. Dhingra R, Vasan RS. Age as a risk factor. Med Clin North Am.2012;96(1):87-91.
39. Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of
montelukast in placebo-controlled pediatric studies and their open-label
extensions. Pediatr Pulmonol. 2009;44(6):568-579.